These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34330018)

  • 1. Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma.
    Meinl E; Krumbholz M
    Curr Opin Immunol; 2021 Aug; 71():117-123. PubMed ID: 34330018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
    Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
    Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity.
    Hoffmann FS; Kuhn PH; Laurent SA; Hauck SM; Berer K; Wendlinger SA; Krumbholz M; Khademi M; Olsson T; Dreyling M; Pfister HW; Alexander T; Hiepe F; Kümpfel T; Crawford HC; Wekerle H; Hohlfeld R; Lichtenthaler SF; Meinl E
    J Immunol; 2015 Jan; 194(2):542-52. PubMed ID: 25505277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
    Pont MJ; Hill T; Cole GO; Abbott JJ; Kelliher J; Salter AI; Hudecek M; Comstock ML; Rajan A; Patel BKR; Voutsinas JM; Wu Q; Liu L; Cowan AJ; Wood BL; Green DJ; Riddell SR
    Blood; 2019 Nov; 134(19):1585-1597. PubMed ID: 31558469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
    Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
    J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. γ-Secretase directly sheds the survival receptor BCMA from plasma cells.
    Laurent SA; Hoffmann FS; Kuhn PH; Cheng Q; Chu Y; Schmidt-Supprian M; Hauck SM; Schuh E; Krumbholz M; Rübsamen H; Wanngren J; Khademi M; Olsson T; Alexander T; Hiepe F; Pfister HW; Weber F; Jenne D; Wekerle H; Hohlfeld R; Lichtenthaler SF; Meinl E
    Nat Commun; 2015 Jun; 6():7333. PubMed ID: 26065893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement.
    Schuh E; Musumeci A; Thaler FS; Laurent S; Ellwart JW; Hohlfeld R; Krug A; Meinl E
    J Immunol; 2017 Apr; 198(8):3081-3088. PubMed ID: 28283566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.
    Nelke J; Medler J; Weisenberger D; Beilhack A; Wajant H
    MAbs; 2020; 12(1):1807721. PubMed ID: 32840410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.
    Robinson T; Abdelhak A; Bose T; Meinl E; Otto M; Zettl UK; Dersch R; Tumani H; Rauer S; Huss A
    Cells; 2020 Nov; 9(12):. PubMed ID: 33255854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.
    Lee L; Draper B; Chaplin N; Philip B; Chin M; Galas-Filipowicz D; Onuoha S; Thomas S; Baldan V; Bughda R; Maciocia P; Kokalaki E; Neves MP; Patel D; Rodriguez-Justo M; Francis J; Yong K; Pule M
    Blood; 2018 Feb; 131(7):746-758. PubMed ID: 29284597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers.
    Wong DP; Roy NK; Zhang K; Anukanth A; Asthana A; Shirkey-Son NJ; Dunmire S; Jones BJ; Lahr WS; Webber BR; Moriarity BS; Caimi P; Parameswaran R
    Nat Commun; 2022 Jan; 13(1):217. PubMed ID: 35017485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis.
    Ho S; Oswald E; Wong HK; Vural A; Yilmaz V; Tüzün E; Türkoğlu R; Straub T; Meinl I; Thaler F; Kümpfel T; Meinl E; Mader S
    Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36702538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma.
    Miao YR; Thakkar K; Cenik C; Jiang D; Mizuno K; Jia C; Li CG; Zhao H; Diep A; Xu Y; Zhang XE; Yang TTC; Liedtke M; Abidi P; Leung WS; Koong AC; Giaccia AJ
    J Exp Med; 2022 Sep; 219(9):. PubMed ID: 35881112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Features of Isoforms of Human Soluble TACI.
    Fichtner ML; Rübsamen H; Smolle M; Schaller J; Feederle R; Bültmann A; Kümpfel T; Schneider P; Thaler FS; Meinl E
    J Immunol; 2023 Jul; 211(2):199-208. PubMed ID: 37272840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma.
    Sanchez E; Smith EJ; Yashar MA; Patil S; Li M; Porter AL; Tanenbaum EJ; Schlossberg RE; Soof CM; Hekmati T; Tang G; Wang CS; Chen H; Berenson JR
    Target Oncol; 2018 Feb; 13(1):39-47. PubMed ID: 29230672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
    Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
    Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble B-cell maturation antigen in multiple myeloma.
    Costa BA; Ortiz RJ; Lesokhin AM; Richter J
    Am J Hematol; 2024 Apr; 99(4):727-738. PubMed ID: 38270277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APRIL is overexpressed in cancer: link with tumor progression.
    Moreaux J; Veyrune JL; De Vos J; Klein B
    BMC Cancer; 2009 Mar; 9():83. PubMed ID: 19291294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.
    Day ES; Cachero TG; Qian F; Sun Y; Wen D; Pelletier M; Hsu YM; Whitty A
    Biochemistry; 2005 Feb; 44(6):1919-31. PubMed ID: 15697217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.
    Moreaux J; Legouffe E; Jourdan E; Quittet P; Rème T; Lugagne C; Moine P; Rossi JF; Klein B; Tarte K
    Blood; 2004 Apr; 103(8):3148-57. PubMed ID: 15070697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.